|
|
Rima McLeod, M.D.
Immunobiology of Toxoplasmosis
Research Summary
Toxoplasmosis causes loss of sight, hearing and brain
damage in congenitally infected individuals. It also causes substantial
morbidity and mortality in individuals immunocompromised by organ
transplantation, malignancy or vasculitis and their therapy or AIDS.
Our laboratory has discovered Toxoplasma gondii specific
secretory IgA (mouse and human) which can block T. gondii invasion of
enterocytes, T. gondii specific cytolytic T cells, and demonstrated
that a temperature sensitive mutant T gondii can confer protection
against peroral and congenital T. gondii infection in a murine model.
We have also demonstrated marked differences in genetic susceptibility
to this infection and identified some of the responsible genetic loci.
In separate experiments, we have discovered T. gondii antigen specific
unresponsiveness in congenitally infected infants.
Our current experiments involve protective and harmful
immune responses (in mice and humans) and constructing recombinant
vectors for delivery of those epitopes that elicit protective immunity.
Specifically, our research involves (1) defining T.Gondii epitopes
recognized by protective CTL lymphocytes, (2) determining whether the
critical protective immune function is cytolytic T cell function or
gamma interferon production or both, and (3) incorporating the genes
which encode proteins which contain epitopes that elicit protection
into a DNA vaccine. This construct will be used to immunize human MHC
transgenic mice (on a susceptible H-2b background) to
determine whether it will protect against peroral and congenital
infection.
We also are characterizing immunogenetics and
pathogenesis and protection in this infection.
Selected Papers
Brown C, David C, Kahn SJ and McLeod R. (1994). Effect
of human
MHC class I genes on outcome of T. gondii cyst formation. J Immunol,
152:4537-41.
McLeod R, Buschman E, Arbuckle LD and Skamene E. (1995).
Immunogenetics in the analysis of resistance to intracellular
pathogens. R Ahmed and A Sher (Eds.). Immunity to InfectionCurrent
Opinion in Immunol, 7:539-552.
Roberts F, Roberts CW, Johnson J, Kyle DE, Krell T,
Coggins JR, Coombs GH, Milhous WK, Tzipori S, Ferguson DJP, Chakrabarti
D, McLeod R. (1998). Evidence for the shikimate pathway in apicomplexan
parasites. Nature, 393:801-805.
Mack D, Johnson J, Roberts F, Roberts C, Estes R, David
C, Grumet C, Estes R and McLeod R. (1999). HLA-Class II genes modify
outcome of
Toxoplasma gondii infection. (Rapid Communication) Int'l J Parasitol,
29:1351-1358.
Kirisits M, Mui E, McLeod R. (2000). Measurement of the
efficacy
of vaccines and antimicrobial therapy against infection with Toxoplasma
gondii. Int'l J. for Parasitol., In Press.
Johnson J,
Roberts CW, Pope C, Roberts F, Kirisits MJ, Estes R, Mui E, Krieger T,
Brown C, Forman J, and McLeod R. (2002). In vitro correlates
of Ld restricted resistance to toxoplasmic encephalitis and
their critical dependence on parasite strain. J.Immunol
169:966-973.
Samuel BJ,
Hearn B, Mack DG, Wender P, Rothbard J, Kirisits M, Mui E, Roberts C,
Prigge S, Rice D, Muench SP, Law A, and McLeod R. (2003). Delivery of
antimicrobials into parasites. PNAS Nov
25;100(24):14281-6.
Roberts C,
Roberts F, Henriquez F, Akiyoshi D, Samuel BU, Richards TA, Milhous W,
Kyle D, McIntosh L, Hill GC, Chaudhuri M, Tzipori S and McLeod R.
(2004).
Evidence for mitochondrial-derived alternative oxidase in the
apicomplexan parasite Cryptosporidium parvum: a potential
anti-microbial agent target. IJP 34:297-308.
Ferguson
DJP, Henriquez FL, Kirisits MJ, Muench SP, Prigge ST, Rice DW, Roberts
CW, McLeod RL. (2005). Maternal inheritance and stage specific
variation
of the apicoplast in Toxoplasma gondii during development in
the intermediate and definitive host. Euk Cell 4(4):814-26.
McLeod R, Boyer K, Karrison T, Kasza K,
Jalbrzikowski J et al. (2006). Outcomes for treated children with
congenital
toxoplasmosis: NCCCTS 1981-2004. CID 42:1383-94.
Richards
TA, Campbell SA, Dacks JB, Blanchard JL, Foster PG, McLeod R, Roberts
CW. (2006). The shikimate pathway in eukaryotes: widespread and
ancient,
lost, replaced or retained. Euk Cell. In
Press.
Muench S, Prigge S, Rafferty J, McLeod R,
Kirisits M, Roberts CW, Mui E and Rice D. (2006). Studies on inhibitor
binding
studies to enoyl acyl carrier protein reductases from the
apicomplexans, Toxoplasma gondii and Plasmodium
falciparum. Acta Crystallography D In Press.
|
Faculty and Research
Programs
|